论文部分内容阅读
目的:评价欣普贝生(地诺前列酮)对胎膜早破足月孕妇引产的有效性和安全性。方法:选取计划分娩的单胎初产妇200例,随机分为实验组(欣普贝生治疗组)100例和对照组(缩宫素治疗组)100例。比较两组宫颈Bishop评分、用药效果、新生儿结局及不良反应。结果:实验组与对照组用药前后宫颈Bishop评分差值分别为(6.59±1.68)分与(4.92±1.71)分,差异有统计学意义(t=6.963,P<0.001);实验组阴道分娩率(87.00%)高于对照组(71.00%)(χ2=7.715,P=0.005);两组总产程、羊水浑浊率差异均有统计学意义(P<0.05);而两组出血量比较差异无统计学意义(P=0.169)。欣普贝生和缩宫素临床使用均无严重不良反应。结论:欣普贝生(地诺前列酮)是一种有效的促宫颈成熟和引产药物,使用方便、安全可靠、适用于胎膜早破足月引产。
PURPOSE: To evaluate the efficacy and safety of Hinbubexone (dinoprostone) in induction of labor during term premature rupture of membranes in pregnant women. Methods: A total of 200 singleton primiparous women were enrolled in this study. They were randomly divided into experimental group (100 cases) and control group (oxytocin treatment group). The Bishop cervical score, medication effect, neonatal outcome and adverse reactions were compared between the two groups. Results: The differences of cervical Bishop scores between the experimental group and the control group before and after treatment were (6.59 ± 1.68) points and (4.92 ± 1.71) points respectively, the difference was statistically significant (t = 6.963, P <0.001). The vaginal delivery rate (87.00%) was higher than that of the control group (71.00%) (χ2 = 7.715, P = 0.005). There was significant difference in the turbidity rate between the two groups (P <0.05) Statistical significance (P = 0.169). There are no serious adverse reactions in the clinical use of Hippophae and oxytocin. Conclusion: Enopbendan (dinoprostone) is an effective cervical ripening and induction drugs, easy to use, safe and reliable, suitable for full-term premature rupture of membranes induced abortion.